Why IGF-1-LR3 Cancels Out Your GH Secretagogues

Watch the full video on Rumble: https://rumble.com/v7fcffc-why-igf-1-lr3-cancels-out-your-gh-secretagogues.html

Why IGF-1-LR3 Cancels Out Your GH Secretagogues

The growth hormone axis runs in a loop, and once you see the loop, most of the confusion around stacking peptides disappears.

Your hypothalamus signals the pituitary to pulse out growth hormone, and that growth hormone travels to the liver, where it gets converted into IGF-1, which is the compound that actually does most of the work people credit growth hormone for. Then IGF-1 circulates back to the brain and triggers something called somatostatin, which is the brake on the whole system. Somatostatin shuts the pituitary up for a while, growth hormone output drops, IGF-1 drops, the brake releases, and the cycle starts again.

That loop is the entire reason people argue about whether you can run IGF-1-LR3 alongside growth hormone. The argument goes that adding external IGF-1 raises the signal that triggers the brake, so you suppress yourself and lose more than you gain.

Where you are in the chain decides whether that argument means anything.

We have to understand that somatostatin suppresses growth hormone release from the pituitary gland, right? It's not going to affect the activity of growth hormone that's already in your bloodstream. That second part is what I have seen play out with clients, and I have never seen a study land on it directly, so treat it as my read rather than something the literature has answered.

And since we're injecting the growth hormone exogenously and we're skipping the pituitary gland completely, that whole argument kind of collapses on itself.

Think of the pituitary as a factory and your bloodstream as the warehouse, since somatostatin's whole job is closing down the factory floor. It does not walk into the warehouse and take back the boxes that already shipped. If you are trucking product in from outside, closing the factory costs you nothing you were counting on.

So adding the additional IGF-1-LR3 really isn't creating any more or less suppression that you would already create it on the axis. Exogenous growth hormone is already raising circulating IGF-1 on its own, and that elevated IGF-1 is already pressing the brake before you add anything.

So it's not costing you anything more or less functionally because at this point, we're already skipping the pituitary gland completely.

Flip the setup and the math changes entirely, because if I was on CJC, tesamorelin with ipamorelin and I was using IGF-1-LR3, in that case, it wouldn't make sense.

Secretagogues work by asking the pituitary to make growth hormone rather than handing you any directly. CJC-1295 extends the releasing signal, ipamorelin triggers a pulse through a separate receptor, and tesamorelin works on the same releasing pathway with a longer half life. Every one of them depends on a pituitary that is willing to answer.

But if you're on secretagogues, adding the IGF-1 is basically going to render these useless. That is my read on the mechanism, and I have not seen a trial that tested that specific stack, so I am telling you what the loop predicts rather than what has been measured.

The reason the loop matters at all is that IGF-1 is the endpoint you actually want. Work in kidney disease found that in uraemia the growth hormone signal is present but the IGF-1 response downstream is blunted, and growth stalls even with hormone in circulation, which is a clean example of the chain breaking at one link while the rest of it looks normal.

Boiled down, the guidance fits in two lines. Running growth hormone, you can add IGF-1-LR3 without a suppression argument against you, because the pituitary is already out of the equation. Running secretagogues, pick one or the other, because IGF-1-LR3 attacks the exact system your secretagogues are paying to stimulate.

Everyone treats suppression as a single risk that follows the compound around. It follows the pathway instead, and the same molecule is either free or expensive depending on which link in the chain you are standing on.

Research citation: Tönshoff, Schaefer, and Mehls documented this disturbance of the growth hormone-insulin-like growth factor axis in uraemia, published in Pediatric Nephrology in 1990.

References:

Tönshoff B, Schaefer F, Mehls O. Disturbance of growth hormone--insulin-like growth factor axis in uraemia. Implications for recombinant human growth hormone treatment. Pediatr Nephrol. 1990. https://pubmed.ncbi.nlm.nih.gov/2088470/